08:31 AM EDT, 03/26/2025 (MT Newswires) -- Leap Therapeutics ( LPTX ) said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.

Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.

The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.

The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.

The company's shares were up more than 18% in recent Wednesday premarket activity.